Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Which accomplishments do you feel he should have achieved at this point?
The only accomplishment I've been waiting for is a monetary deal either for AXAL or HOT. Although your list of his accomplishments is well known, these are either minor or late moves. Cutting a workforce turned into a hiring spree -- I've seen from 4 to 6 vacancies since late June. Why is that?
The real killer has been a poisonous dilution with warrants capped with Ken getting his 150K bonus. I could hardly put those into "accomplishments" column. Sorry for the early morning rant.
@wmtgreeter
PS. DD here now stands for Deal or Dilution. Nothing in between.
Because there's none...
Tuesday morning tidbit:
Ken Berlin has been a CEO of Advaxis for exactly six months.
Below is the complete list of his accomplishments:
There have not been any insider buys since the June when positivists touted those small open market purchases by the management. Those shares are now worth 1/3rd of their original investment.
Management must get desperate at this point and needs to do something.
G-d forbid if it's a clinical hold. This company would be finished then.
Market cap is just $42M, just $12M above of the point of no return.
It's really sad and pathetic that they still retain LHA for IR purposes when they need to hunker down and cut all fat and pork. They have Ranya Dajani, a glorified VP for Business Development, whose sole job duties are to prepare and sign press releases as she has accomplished nothing since she was hired 27 months ago. Why do they still keep her? Either fire her, or cut LHA. Bolivar cannot carry double!
Also, the negative market reaction should have been anticipated and steps to mitigate that negativity had to be taken. They look like amateurs or liars.
ours will likely not be much more explosive than this
I'm guessing that the funds/analysts are fully aware of the current status of our NEO trial as it's an open label CT. There likely have not been earth-shattering miracle cures with the NEO dosing, and this is reflected in the share price and the direction of Advaxis. It's really shortsighted to assume that nobody on the Street knows nothing about our/Amgen trial, and everyone is in the dark with respect to the safety and efficacy. Likely, we will have to wait for Ph2 data to see anything paradigm shifting results. And that's a looong way to go.
B.liu wears rose colored hearing aids, thus, negatives are completely filtered out, just positives transmitted and amplified with her BLINDERS subwoofers.
ESMO has been a killer for bio stocks...
Merck's tepid STING data pressures Aduro Biotech, down 24% premarket
Oct. 22, 2018 7:33 AM ET|About: Aduro Biotech (ADRO)|By: Douglas W. House, SA News Editor
Thinly traded small cap Aduro Biotech (NASDAQ:ADRO) is down 24% premarket on light volume in apparent reaction to Merck's announcement of preliminary Phase 1 data on STING agonist MK-1454 at ESMO in Munich. The response rate was 0% in the monotherapy arm in patients with solid tumors or lymphomas.
Aduro's ADU-S100 is also a STING agonist. Preliminary Phase 1 data will be presented at the SITC annual meeting in early November.
https://seekingalpha.com/news/3399155-mercks-tepid-sting-data-pressures-aduro-biotech-24-percent-premarket
ADRO getting killed after ESMO: the stock printed a fresh 52-wk low today (down 42%), and currently down 33%.
Neon Therapeutics presented Ph1 data at ESMO. Looks like the markets are not impressed with their data. The stock is down 12%.
http://globenewswire.com/news-release/2018/10/22/1624508/0/en/Neon-Therapeutics-Presents-Data-from-Ongoing-Phase-1b-NT-001-Clinical-Trial-at-European-Society-for-Medical-Oncology-2018-Congress.html
Ken Berlin deserves a mid-year bonus for all his accomplishments listed below:
You are most likely an AI with 0 sense of humor or irony. Is your brother Zack Investments?
That alone should not prevent him from further prognostications. We need a whole spectrum of opinions, including wrong ones. The contraindications are very valuable when finding the right direction.
It's your money, and it's your decision. If you could walk away from $2M+ losses, then might consider cutting the losses. Did your investment thesis change in the past 6 months or so? If yes, then your decision could be easier.
Personally, I would hold for few more months, to see if they can get a partner for HOT. If not partner by 02/19, then this will get ugly. The NEO data readout is most likely at ASCO-19, not sooner. The company will have tough time surviving by June '19.
Probability of spiraling down the drain is about 75%. That's my estimate.
PS. I'm just a @wmtgreeter. PRO Investors are located in BLUE Building at the corner of Iggyville and Zhang Ave.
Interesting that ECYT had to cut their workforce by 40% and stop a clinical trial before things turned around miraculously. They also paid $12M for a drug that turned out to be a blockbuster. Will the story repeat here for ADXS?
Snip: "Endocyte Inc. ECYT, +50.61% stock plummeted 30.4% in premarket trade Friday after the company said it plans a "strategic restructuring" that includes an about 40% reduction in its workforce and clinical trial changes, including ending enrollment in one trial. The company plans to terminate 47 employees, largely in the third quarter, and said it expects total restructuring costs of about $2.4 million, including severance, clinical trial termination charges and other costs. "The company is continuing to review the potential impact of the restructuring, and is unable to estimate any additional restructuring costs or charges at this time," the company said in its 8-K financial filing on Friday. Endocyte said it is stopping enrollment in a trial for its EC1456 trial, though it will continue to enroll a small number of patients in the compound's ovarian cancer surgical study."
https://www.marketwatch.com/story/endocyte-stock-plummets-30-on-news-of-major-workforce-reduction-clinical-trial-changes-2017-06-02
https://investor.endocyte.com/news-releases/news-release-details/endocyte-announces-exclusive-worldwide-license-phase-3-ready
You are raising extremely valid point: never trust what someone says on the anonymous message board.
I know I do not trust B. Liu. Whatever (s)he posts re: Ken's feedback cannot trusted and needs to verified. It's a red flag when CEO's message is first posted on the message board, not delivered via a conference call. For the same reason, I'm not trusting what someone else's posting here as a "feedback" from the management. With all due respect, that includes you, James.
Those are exactly your words. Some amnesia?
Ok,good news is CVI will pump Adxs sooner or later.
CVI is the big question now,they have 6% and that`s without executing the free warrants. Something`s about to change positive for Adxs.
1) Looking into trading practices? Really? He failed to execute and now funds are bailing. It's just a lip service from Ken.
2) He doesn't get why such a steep drop after the secondary? This is what happens when you do a raise with warrants attached at 3rd tier bank. Can't believe he went to Princeton. He's lying or just incompetent. Either is bad.
3) Now, B. Liu, you have made 180 degree turn re: CVI. Remember when you were touting them, exactly like when Edelman jumped in? Now you started seeing what was obvious to me the first day it showed up on 13F form.
4) Instead of "talking" to a retail holder and wasting his time, Ken should be on the phone talking with various health care funds. BTW, it would not hurt to have a conference call and provide some update of the state of the business.
@wmtgreeter
No wonder Petit stopped buying.
“. I am an idiot. I admit it.”
—————————————-
That makes two of us.
Clinical trial statuses have not been updated for at least 6 months. Even for those discontinued.
3. Stonebridge reduced by 10K shares.
STONEBRIDGE CAPITAL MANAGEMENT INC 49,249 0.03 133 11,000 0.0936% 13F 2018-09-30 2018-10-17
2. Cutler Capital management sold out, all 100K shares.
CUTLER CAPITAL MANAGEMENT, LLC 0.06 Sold All 100,000 0.0000% 13F 2018-09-30 2018-10-17
1. Franklin St Advisors increased their stake by 60K shares.
FRANKLIN STREET ADVISORS INC 190,800 0.03 151 60,000 0.3626% 13F 2018-09-30 2018-10-05
I think it's time for a mid-year evaluation of Ken Berlin.
I'll give him C- for his six month tenure. He demonstrated his inability to execute and deliver. He pulled the EMA application, cut workforce by 24%, and reduced a cash burn to approximately $50M/year, prorated. Struck a weak, cashless deal with OS Therapeutics. Promised to update on AXAL platform during the last CC, and he canceled the call itself. No update, and likely AXAL is now shelved. He diluted, and got his 150K bonus for doing that. Nothing else is publicly available. The morale at the company may not be too high, as they're trying to fill several vacancies due to employees leaving.
No cash deals so far. The big overhang is AXAL. Shelved? Not shelved? PSA combo results? Good? Bad? How they are going to pay for HOT Ph1? Too many questions, and very few answers. The markets abhor the information vacuum. Thus, the selling. Ken has not been able to attract any health care fund, and that's troubling. Enough of the rant.
Funds are unloading their remaining shares. Once new 13F/G forms are filed soon, we will see that institutional ownership dips below 15% -- the lowest level in 7 years, if ever.
Pathetic.
Old warrants are trading at 0.01. Dipped to 1/100 of a penny few days ago. I hope KB lets them expire worthless. Then, we skyrocket as the HFTs will be reprogrammed to make a U-turn...
Date Open High Low Close / Last Volume
10:34 0.0133 0.01 0.01 0.01 13,066
10/16/2018 0.0133 0.0151 0.01 0.01 50,536
10/15/2018 0.019 0.019 0.01 0.0133 10,457
10/12/2018 0.01 0.019 0.01 0.019 19,137
10/11/2018 0.02 0.02 0.01 0.018 17,350
10/10/2018 0.03 0.03 0.03 0.03 1,000
10/09/2018 0.03 0.03 0.0299 0.0299 16,400
10/08/2018 0.02 0.0201 0.02 0.02 1,500
10/05/2018 0.02 0.0399 0.014 0.02 17,348
10/04/2018 0.011 0.04 0.01 0.0372 44,668
10/03/2018 0.02 0.02 0.0001 0.0001 65,177
BTW, dndn no longer exists
We've been printing brand new all time lows daily for the past few days. Does it not tell you how dire the situation is?
It’s up to you, Ken!
good-bye my Warrants
That's not correct. Once they deficiency notice, the company has 180 calendar days to get in compliance. That may or may not get extended based on the circumstances. They actually could run out of money by that time if nothing positive happens.
My threshold is $30M for a market cap. If the company dips below that level, it's likely will be done.
We are likely to see 8-K after the close. Nasdaq delisting/warning notice. 30 trading days since we are sub $1.
make it 0.70
Nauseating...
That's a great thing! And then a lift off that many long-term promoters predicted for so long! To da Moon!
Human Papillomavirus and Related Diseases Report
http://www.hpvcentre.net/statistics/reports/RUS.pdf
Advaxis should be targeting that vast market. instead, we are shelving what was supposed to be our cash cow...
SOME KEY STATS:
(*) About 15,342 new cervical cancer cases are diagnosed annually in the
Russian Federation (estimations for 2012).
(*) Cervical cancer ranks* as the 5th leading cause of female cancer in the Russian Federation.
(*) About 7,371 cervical cancer deaths occur annually in the Russian
Federation (estimations for 2012).
(*) Cervical cancer ranks* as the 7th leading cause of female cancer deaths in the Russian Federation.
(*) Cervical cancer is the 1st leading cause of cancer deaths in women
aged 15 to 44 years in the Russian Federation.
While we wait for Ph3 to start, DOC started Ph2 in collaboration with Merck:
OncoSec Initiates KEYNOTE-890, a Phase 2 Clinical Trial of TAVO in Combination with Merck's KEYTRUDA® (pembrolizumab) for the Treatment of Late-Stage Triple Negative Breast Cancer
https://ir.oncosec.com/press-releases/detail/1961/oncosec-initiates-keynote-890-a-phase-2-clinical-trial-of
Another all time low has been printed at 0.75.
the science is valued at less then zero.
Sorry, that was a typo. Need to strengthen my math skills by redoing my GED next year.
@wmtgreeter